Evaluation of serum copeptin and heart-fatty acid binding protein as predictor biomarkers for chronic diabetic kidney disease in Egyptian Patients
Paper Details
Evaluation of serum copeptin and heart-fatty acid binding protein as predictor biomarkers for chronic diabetic kidney disease in Egyptian Patients
Abstract
Chronic diabetic kidney disease and diabetic nephropathy are the leading cause of end-stage kidney disease in developed countries. The objective of this study is to evaluate s-copeptin and heart-fatty acid binding protein (H-FABP) as predictor markers of chronic diabetic kidney disease (CDKD) in type 2 Egyptian diabetic patients. Ninety five volunteers were classified as follows: group I comprised 20 normal subjects, group II consisted of 15 hypertensive patients, group III included 30 type 2 diabetic patients (T2D) with normal renal function, and group IV consisted of 15patients with CDKD treated with renin angiotensin aldosterone system inhibitors and group V comprised15 patients with un-treated CDKD. Serum copeptin, H-FABP, diabetic and renal biomarkers were determined. Highly significant increase in s-copeptin level (p<0.001) in hypertensive, treated CDKD and untreated CDKD group compared to control subjects, while a non-significant change were observed in T2DM group. A moderate increased in H-FABP level was recorded in both treated and untreated CDKD group compared to control subjects. Also, s-creatinine significantly increased in both groups of CDKD. On the other hand, e-GFR, showed highly significant decrease (p<0.001) in CDKD groups, compared to other groups. The diagnostic performance study revealed that, s-copeptin and HFABP showed a less diagnostic value in T2D patient group. In hypertensive patient group s-copeptin showed highest diagnostic information, while H-FABP showed a less accuracy. However in CDKD patient groups, s-creatinine and s-copeptin provided the highest diagnostic value followed by H-FABP according to the area under the curve.Hence, s-copeptin is helpful for the identification of chronic diabetic kidney disease (treated and/or untreated) patients with high risk for a decline in renal function.
Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. 2000. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney International 58(5), 2129–37.
Baris Afsar. 2017. Pathophysiology of copeptin in kidney disease and hypertension. Clinical Hypertension 23, 13. http://dx.doi.org/10.1186/s40885-017-0068-y.
Burkhardt H, Bojarsky G, Gretz N, Gladisch R. 2002. Creatinine clearance; Cockcroft-Gault formula and cystatin C: estimator of true glomerular filtration rate in the elderly; Gerontology 48(3), 140-146.
Chih-Hung L., Yi-Cheng C, Lee-Ming C. 2016. Early detection of diabetic kidney disease: Present limitations and future perspectives. World Journal of Diabetes 7, 290-301.
Eman M. Abd El Azeem, Dina M. Seoudi, Mustafa I. Hassanein, Marwa A. Hussein. 2017. U-Lfabp as a Predictive Marker for Prognosis of diabetic Kidney Disease in Egyptian Patients. European Journal of Biomedical and Pharmaceutical Sciences. 4(4), 83-90.
Grey V, Perlas M, Aebi C. 1996. Immunoturbidimetric method for determination of hemoglobin A1c. Clinical Chemistry 42(12), 2046–7.
Huimei Chen, Chunxia Zheng, Qing Gao, Yongchun Ge, Zhihong Liu. 2012. Heart-type fatty acid binding protein is associated with proteinuria in obesity. PLoS One. 7, e45691. http://dx.doi.org/10.1371/journal.pone.0045691.
Jian G, Yan Y, Li J, Wang N. 2014. Ambulatory blood pressure as a predictor of diabetic nephropathy. Journal of Integrative Nephrology & Andrology 1, 29-32.
Jo YH, Kim K, Lee JH, Rhee JE, Lee JH, Kang KW. 2012. Heart-type fatty acid-binding protein as a prognostic factor in patients with severe sepsis and septic shock. American Journal of Emergency Medicine 30, 1749–55. http://dx.doi.org/10.1016/j.ajem..02.005.
Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H. 2006. Copeptin and arginine vasopressin concentrations in critically ill patients. Journal of Clinical Endocrinology Metabolism 91, 4381–6. http://dx.doi.org/10.1210/jc.2005-2830.
Karbek Basak, Mustafa Özbek, Nujen Colak Bozkurt, Zeynep Ginis, Askın Güngünes, İlknur Öztürk Ünsal, Erman Cakal Tuncay Delibas. 2011. Heart-Type Fatty Acid Binding Protein (H-FABP): Relationship with arterialıntima-media thickness and role asdiagnostic marker for atherosclerosis in patients withımpaired glucosemetabolism. Cardiovascular Diabetology, 10(37), 1415–25.
Kausik Umanath, Julia B. Lewis. 2018. Update on Diabetic Nephropathy: Core Curriculum 2018, Published on February 02, 2018.
Kimura H, Fujii H, Suzuki S, Ono T, Arakawa M, Gejyo F. 1999. Lipid-binding proteins in rat and human kidney. Kidney International 56, S159–162. http://dx.doi.org/10.1046/j.1523-1755.1999.07141.x.
Kramer C, Leitao C, Pinto L, Silveiro S, Gross J, Canani L. 2007. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care, 30, 1998-2000.
Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Nakao K. 2014. Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy. Clinical Experimental Nephrology; 18, 584-592.
Magda Kamal Ezz, Eman M, Abd El Azeem. 2016. Assessment of Progranulin in Egyptian type 2 diabetic patients as a novel biomarker for diabetic nephropathy International Journal of Biosciences | IJB | 9(6), p 350-359.
Mauer M., Zinman B, Gardiner R. 2009. Renal and retinal effects of enalapril and losartan in type 1 diabetes. The new England Journal of medicine 361, 40-51.
Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort R. 2010. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney International 77, 29–36. http://dx.doi.org/10.1038/ki.2009.397.
Meijer E, Bakker SJL, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort R. 2011. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clinical Journal American Socity and Nephrology 6, 361–8. http://dx.doi.org/10.2215/CJN.04560510.
Nelson RG, Pettitt DJ, Knowler WC, Bennett PH. 1995. Prediabetic blood pressure and familial predisposition to renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. journal of Diabetes Complications 9, 212-4.
Ponte B, Pruijm M, Ackermann D, Vuistiner P, Guessous I, Ehret G, Alwan H, Youhanna S, Paccaud F, Mohaupt M, Péchère-Bertschi A, Vogt B, Burnier M, Martin PY, Devuyst O, Bochud M. 2015. Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. Clinical Journal of American Society Nephrology 26, 1415–25. http://dx.doi.org/10.1681/ASN.2014030260.
Shahbazian H, Rezaii I. 2013. Diabetic Kidney disease; review of the current knowledge. Journal of Renal Injury Prevention 2(2), 73-80.
Sofia Enhörning, Anders Christensson, Olle Melander. 2019. Plasma copeptin as a predictor of kidney disease. Nephrology Dialysis Transplantation 34(1), 74–82, https://doi.org/10.1093/ndt/gfy017.
Steinke J, Mauer M. 2008. International Diabetic Nephropathy Study Group. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patient. Pediatric Endocrinology Review. 5, 958–963.
Struck J, Morgenthaler NG, Bergmann A. 2005. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26, 2500–4. http://dx.doi.org/10.1016/j.peptides.2005.04.019.
Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, Christ-Crain M. 2007. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. Journal of Clinical Endocrinology Metabolism 92, 3973–8. http://dx.doi.org/10.1210/jc.2007-0232.
Temesgen F, Zemenu T. 2016. Urinary Markers of Tubular Injury in Early Diabetic Nephropathy (Review Article). Hindawi Publishing Corporation International Journal of Nephrology; Article ID 4647685.
Trinder P. 1969. Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor. Annals of Clinical Biochemistry 6, 24-25.
Undurti N. Das. 2016. Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease. Indian Heart Journal. 68(1), 16–18. https://doi.org/10.1016/j.ihj.2015.07.030.
Uslu S, Efe B, Alata O, Kebapçi N, Colak O. 2005. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. Journal Nephrology 18, 559 67.
Vallon V. 2011. The proximal tubule in the pathophysiology of the diabetic kidney. American Journal of Physiology–Regulatory, Integrative and Comparative Physiology 300, R1009–R1022.
Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M. 2005. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54, 2328-2335.
Zhang Y, Ma XKL, Liu J, Wu Y, Hu ZB, Liu L, Liu BC. 2015. Dysregulation of low-density lipoprotein receptor contributes to podo injuries in diabetic nephropathy. American Journal of Physiology Endocrinology Metabolism; 308, E1140-E1148.
Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort R. 2012. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clinical Journal of American Society Nephrology 7, 906–13. http://dx.doi.org/10.2215/CJN.11311111.
Zuo N, Suzuki Y, Sugaya T, Osaki K, Kanaguchi Y. 2011. Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy. Nephrology Dialysis Transplantation 26, 2127–2137.
Hala M. El-Sebaii, Atef A. Bassyouni, Dina M. Seoudi, Eman M. Abd El Azeem, 2019. Evaluation of serum copeptin and heart-fatty acid binding protein as predictor biomarkers for chronic diabetic kidney disease in Egyptian Patients. Int. J. Biosci., 14(5), 515-525.
Copyright © 2019 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.